WO2018177182A1 - 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪 - Google Patents

利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪 Download PDF

Info

Publication number
WO2018177182A1
WO2018177182A1 PCT/CN2018/079879 CN2018079879W WO2018177182A1 WO 2018177182 A1 WO2018177182 A1 WO 2018177182A1 CN 2018079879 W CN2018079879 W CN 2018079879W WO 2018177182 A1 WO2018177182 A1 WO 2018177182A1
Authority
WO
WIPO (PCT)
Prior art keywords
light
disease
light source
portable therapeutic
optic nerve
Prior art date
Application number
PCT/CN2018/079879
Other languages
English (en)
French (fr)
Inventor
关一夫
Original Assignee
关一夫
辽宁中盛凯尔医疗器械有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 关一夫, 辽宁中盛凯尔医疗器械有限公司 filed Critical 关一夫
Priority to CN201880006540.7A priority Critical patent/CN111867676A/zh
Publication of WO2018177182A1 publication Critical patent/WO2018177182A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0622—Optical stimulation for exciting neural tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/04—Eye-masks ; Devices to be worn on the face, not intended for looking through; Eye-pads for sunbathing
    • A61F9/045—Eye-shades or visors; Shields beside, between or below the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient
    • A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
    • A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes

Definitions

  • the invention relates to the fields of neurobiology, biochemistry, physiology, therapeutic instruments for degenerative diseases of the elderly and the like.
  • AD Alzheimer disease
  • AD also known as Alzheimer's disease
  • AD is a central nervous system degenerative disease, insidious onset, slow course, continuous, difficult to find early, is the most common one for senile dementia Types.
  • the clinical manifestations of AD are progressive mental state decay, including progressive mental memory disorders, cognitive dysfunction, personality changes, language disorders and other neuropsychiatric symptoms, behavioral disorders and even confusion. AD seriously affects people's social, professional and life functions [1].
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • the currently widely accepted doctrine has deposited plaques formed by the accumulation of A ⁇ -amyloid on the outer surface of brain nerve cells [4], neuronal fibrillation in neuronal cells formed by hyperphosphorylation of tau [5], and Neuronal loss with gliosis and so on.
  • the neurofibrils are entangled in the cytoplasm of the neurons. This neurofibrillary tangles develop to a certain extent, which can degenerate and destroy the neurons, leaving the spiral plaques of silver stains in the middle, and the middle is the amyloid core, ie the senile plaques.
  • a ⁇ -amyloid aggregation in the cerebral cortex and hippocampus is most prevalent, and A ⁇ deposits are also found in the striatum, amygdala and thalamus. Locally, A[beta]-amyloid deposits are a product of the development of neurofibrillary tangles to advanced stages. In addition, AD patients also have neuronal loss, cortical purple pigmentation and astrocytic hyperplasia.
  • AD Alzheimer's disease
  • AD model mice (5XFAD) were placed in a black test chamber, and the mice were stimulated with LED light for one hour: then A ⁇ -soluble protein and A ⁇ -amyloid deposit plaques in the visual cortex of AD mice were examined.
  • Six different stimulation methods were used in the experiment: 20 Hz regulated scintillation light, 40 Hz regulated scintillation light, 80 Hz regulated scintillation light, disordered scintillation light, continuous light, and no light.
  • the results of the assay showed that AD mice stimulated with 40 Hz-regulated LED scintillation light were significantly different.
  • the expression levels of soluble A 1-40 and soluble A 1-42 in the visual cortex of AD mice were reduced by 57.96% and 57.97%, respectively.
  • the same experiment was also validated in another AD model mouse (APP/PS1) experiment. Immunohistochemistry results also showed that there was no change in the number of microglia in the visual cortex of 5XFAD mice, but the diameter of microglia increased by 65.8%.
  • the other five stimulation methods did not change the soluble A 1-40 and soluble A 1-42 expression levels of the mice.
  • the present invention provides a portable therapeutic device that uses LED light to stimulate the eye to treat, ameliorate and prevent Alzheimer's disease.
  • a portable therapeutic device that uses an LED light source to stimulate the eye to treat, improve, and prevent Alzheimer's disease.
  • a portable therapeutic apparatus for treating Alzheimer's disease using light-stimulated optic nerve characterized in that:
  • the treatment device includes:
  • An eye mask that can be attached to a person's face and cover the eye
  • a power source that supplies energy to the light source
  • a control element that regulates changes in the light source.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulating optic nerve is characterized in that the eye mask is an eye mask made of an opaque material.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulation optic nerve is characterized in that the light source is fixed on one side of the eyecup contacting the face.
  • the light source is an annular light source array composed of a plurality of point light sources, and two annular light source arrays are arranged on the eye mask.
  • the two annular light source arrays cover the eyes.
  • the point light source is a light emitting diode, and the light emitting diode is circular or square.
  • the circular light-emitting diode has a diameter of 2 - 5 mm.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulation optic nerve is characterized in that: the annular array consisting of the point light sources is filled with other point light sources, and the arrangement is one at the center of the circle, at the center of the circle 6 between the ring and the ring.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulating optic nerve is characterized in that the light source has a wavelength of 400-800 nm and a brightness modulation frequency of 40 Hz, wherein the illumination time is 1 - 20 ms. Tune, illuminance is 20 – 2000 lux.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulation optic nerve is characterized in that the power source is a power supply device connected to a light source through a power line.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulating optic nerve is characterized in that the power source is a battery fixed to an eye mask.
  • the portable therapeutic device for treating Alzheimer's disease by using light stimulating optic nerve is characterized in that the control element is a controller for adjusting the brightness frequency of the light fixed on the power supply device.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulating optic nerve is characterized in that the control element is a controller fixed on the eye mask and regulating the frequency of the light brightness by receiving an instruction sent by the mobile communication device.
  • the portable therapeutic apparatus for treating Alzheimer's disease by using light stimulation optic nerve is characterized in that the annular light source array is composed of 12 point light sources.
  • the portable therapeutic device has the characteristics of simple operation, convenient application and high cost performance.
  • the portable therapeutic device is not only suitable for medical institutions at all levels (high-end top three hospitals, community hospitals, township hospitals), but also for various types of rehabilitation institutions, elderly health management institutions, and families.
  • the portable therapeutic device can be used not only in a fixed place, but also as a wearable therapeutic device, and the use is not limited by location and time. This portable therapeutic device will be mainly used for the treatment and improvement of patients with Alzheimer's disease, and for the prevention of Alzheimer's disease in the middle-aged and elderly population.
  • 1 and 2 are schematic views showing the distribution of the eye mask and the LED light source inside the eye mask
  • T2 is the LED light source lighting time.
  • the treatment device includes:
  • An eye mask that can be attached to a person's face and cover the eye
  • a power source that supplies energy to the light source
  • a control element that regulates changes in the light source.
  • the eye mask is an eye mask made of an opaque material.
  • the light source is fixed on one side of the eye contact contacting the face;
  • the light source is an annular light source array composed of a plurality of point light sources, and two annular light source arrays are arranged on the eye cover, and when the eye cover covers both eyes, the two annular light source arrays cover the eyes on.
  • the light source adopts a circular light-emitting diode with a diameter of 2 mm;
  • the annular array composed of the point light source is filled with other point light sources, and the arrangement is one at the center of the circle and six at the center of the circle and the ring.
  • the light source has a wavelength of 600 nm and a brightness modulation frequency of 40 Hz, with a bright time of 1 – 20 ms and an illumination of 1500 lux.
  • the invention relates to a portable therapeutic apparatus for treating Alzheimer's disease by using light stimulating optic nerve, and the technical idea thereof is to stimulate the eye of a patient by LED light to achieve the effect of treating, improving and preventing Alzheimer's disease.
  • a portable therapeutic apparatus for treating Alzheimer's disease using light-stimulated optic nerve characterized in that:
  • the treatment device includes:
  • An eye mask that can be attached to a person's face and cover the eye
  • a power source that supplies energy to the light source
  • a control element that adjusts the change in brightness of the source.
  • the eye shield is an eye mask made of an opaque material, preferably black.
  • the light source is fixed to the side of the eyecup that contacts the face.
  • the light source is an array of annular light sources composed of a plurality of point light sources, and two annular light source arrays are arranged on the eye mask. When the eye cover covers both eyes, the two annular light source arrays cover the eyes.
  • the light source is preferably arranged in a laterally elliptical ring shape.
  • the point source is a light-emitting diode
  • the light-emitting diode is circular or square, and for a circle, preferably has a diameter of 2 - 5 mm.
  • annular array of point sources is filled with other point sources, preferably one at the center of the circle and six between the center of the circle and the ring.
  • the focus of the invention to achieve therapeutic effects lies in the parameters of the light source, as shown in FIG. 3, specifically: the light source has a wavelength of 400-800 nm, the brightness modulation frequency is 40 Hz, and the illumination time is adjustable from 1 to 20 milliseconds. The illuminance is 20 – 2000 lux. After extensive experiments and research by the inventors, the above parameters of the light source can effectively treat and improve the patient's disease state.
  • the power source is a power supply device connected to the light source through a power line. Or a battery that is attached to the eye shield.
  • the control element is a controller that adjusts the brightness of the light on the power supply unit. Or a controller that is fixed to the eyecup to regulate the brightness frequency by receiving an instruction sent by the mobile communication device.
  • the annular light source array is composed of 12 point light sources, and the effect is better.
  • the mobile communication device includes a mobile phone, a wristwatch or a wearable device.
  • the method of use of the present invention is as follows:
  • an elastic strap to secure the eye shield to the face and cover the eye, adjusting the elastic strap to comfort.
  • the brightness can be adjusted by setting the T2 time according to personal comfort.
  • the setting range of T2 time is 1 - 20 ms (T1 time has been fixed to 25 ms).
  • one of the treatment options for light scintillation stimulation can be selected: (1) 15 minutes/time, 4 times/day; (2) 30 minutes/time, 2 times/day; (3) 60 minutes / time, 1 time / day. Every seven days is a course of treatment.
  • the treatment device includes:
  • An eye mask that can be attached to a person's face and cover the eye
  • a power source that supplies energy to the light source
  • a control element that regulates changes in the light source.
  • the eye mask is an eye mask made of an opaque material.
  • the light source is fixed on one side of the eye contact contacting the face;
  • the light source is an annular light source array composed of a plurality of point light sources, and two annular light source arrays are arranged on the eye cover, and when the eye cover covers both eyes, the two annular light source arrays cover the eyes on.
  • the light source adopts a circular light-emitting diode with a diameter of 2 mm;
  • the annular array composed of the point light source is filled with other point light sources, and the arrangement is one at the center of the circle and six at the center of the circle and the ring.
  • the light source has a wavelength of 600 nm and a brightness modulation frequency of 40 Hz, with a bright time of 1 – 20 ms and an illumination of 1500 lux.
  • the treatment device includes:
  • An eye mask that can be attached to a person's face and cover the eye
  • a power source that supplies energy to the light source
  • a control element that regulates changes in the light source.
  • the eye mask is an eye mask made of an opaque material.
  • the light source is fixed on one side of the eye contact contacting the face;
  • the light source is an annular light source array composed of a plurality of point light sources, and two annular light source arrays are arranged on the eye cover, and when the eye cover covers both eyes, the two annular light source arrays cover the eyes on.
  • the light source uses a circular light-emitting diode with a diameter of 5 mm; the light source has a wavelength of 600 nm and a brightness modulation frequency of 40 Hz, wherein the light-on time is adjustable from 1 to 20 milliseconds and the illumination is 20 lux.
  • the treatment device includes:
  • An eye mask that can be attached to a person's face and cover the eye
  • a power source that supplies energy to the light source
  • a control element that regulates changes in the light source.
  • the eye mask is an eye mask made of an opaque material.
  • the light source is fixed on one side of the eye contact contacting the face;
  • the light source is an annular light source array composed of a plurality of point light sources, and two annular light source arrays are arranged on the eye cover, and when the eye cover covers both eyes, the two annular light source arrays cover the eyes on.
  • the light source uses a circular light-emitting diode with a diameter of 5 mm; the light source has a wavelength of 600 nm and a brightness modulation frequency of 40 Hz, wherein the light-on time is adjustable from 1 to 20 milliseconds and the illumination is 2000 lux.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

本发明是一种利用光刺激视觉神经的便携式治疗装置。通过LED光刺激受试者眼部，来达到治疗、改善以及预防阿尔茨海默病的效果。该便携式治疗仪包括：可固定于人面部并覆盖眼部的眼罩；固定在眼罩上的光源；为发光光源提供能量的电源。该便携式治疗仪具有操作简单、应用方便、性价比高的特点。该便携式治疗仪不仅适用于各级医疗机构，而且还适用于各类康复机构、老年健康管理机构以及各个家庭中使用。该便携式治疗仪不仅可以用于固定的场所等，而且还可以作为可穿戴式设备随身携带，使用不受地点和时间的限制。

Description

利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪 技术领域
本发明涉及神经生物学、生物化学、生理学、老年退行性疾病治疗仪器等领域。
 背景技术
阿尔茨海默病（Alzheimer disease，AD），又称老年痴呆病，是一种中枢神经***变性病，起病隐袭，病程缓慢，持续进行，难以早期发现，是老年期痴呆最常见的一种类型。AD的临床表现是进行性精神状态衰变，包括渐进性记忆障碍、认知功能障碍、人格改变、语言障碍等神经精神症状，行为失常甚至发生意识模糊等。AD严重影响了人们的社交、职业与生活功能 [1]。
AD患者初始发病年龄多在50岁以后，并且AD发病率随年龄增高，65岁以上患病率约为5%，85岁以上则为20%，妇女患病率是男性患病率的3倍。AD患者通常在发病后5～6年内死于继发感染和全身衰竭。2011年，哈佛公共卫生学院（Harvard School of Public Health）公布的一份调查报告显示，在欧美主要城市人群中，AD是仅次于癌症的第二大忧患 [2]。到2050年，全球AD患者人数预计从如今的0.44亿增加到1.355亿。日益增加的AD将会导致重大的经济和社会成本 [3]。单在美国，阿尔茨海默病的治疗就需要花费近2,260亿美元。因此人们迫切需要新的预防、诊断和治疗手段。
AD的病因及发病机制尚未阐明。目前得到普遍认可的学说有由于Aβ-淀粉样蛋白聚集在大脑神经细胞外表面上形成的沉积斑块 [4]，tau蛋白过度磷酸化形成的神经细胞内神经原纤维缠结 [5]，以及神经元丢失伴胶质细胞增生等。神经原纤维缠结在神经元胞质中，这种神经原纤维缠结发展到一定程度，可使神经元变性、破坏，残留下嗜银的螺旋斑块，中间为淀粉样核心，即老年斑。Aβ-淀粉样蛋白聚集在大脑皮质和海马的沉积斑块机制最为流行，Aβ沉积斑块还见于纹状体、杏仁核和丘脑。从局部而言，Aβ-淀粉样蛋白沉积斑块是神经原纤维缠结发展到晚期的产物。此外，AD患者脑内还有神经元丧失，皮质紫褐质聚集和星形细胞增生等。
由于AD的病因及发病机制未明，目前尚无特效疗法。常用方法包括药物治疗改善认知功能及记忆障碍；对症治疗改善精神症状；良好的护理延缓病情进展。药物和康复治疗以改进认知和记忆功能，保持患者的独立生活能力，提高生存质量为目的 [6]。但是这些治疗收效甚小，特别是还没有针对溶解和减少Aβ-淀粉样蛋白沉积斑块的有效药物和方法。研究表明，如果在Aβ-淀粉蛋白沉积斑块明显形成后，再针对AD的治疗效果是非常有限的 [6]。迄今为止，阿尔茨海默病是处在一种无法预防、无法早期发现和无法治疗的困境。
大脑对光刺激的反应早已为人所知 [7]，但是，光刺激对阿尔茨海默病人大脑的作用只是在近年得到了人们的关注 [8]。
Icaccarino等人报道了一项研究结果 [9]。将AD模型小鼠（5XFAD）置于黑色试验箱中，利用LED光刺激小鼠一小时：然后检测AD小鼠视觉皮层中的Aβ-可溶性蛋白以及Aβ-淀粉样蛋白沉积斑块。实验选用了六种不同的刺激方法：20赫兹调控的闪烁光、40赫兹调控的闪烁光、80赫兹调控的闪烁光、无序闪烁光、持续光、以及无光。检测结果表明，利用40赫兹调控的LED闪烁光刺激的AD小鼠有明显的不同。AD小鼠视觉皮层中的可溶性A 1-40和可溶性A 1-42表达量分别减少了57.96%和57.97%。相同的实验也在另一种AD模型小鼠（APP/PS1）实验中得到了验证。免疫组化结果还表明，5XFAD小鼠视觉皮层的小胶质细胞的数量没有变化，但是小胶质细胞的直径增加了65.8%。而利用其他五种刺激方法没有改变小鼠的可溶性A 1-40和可溶性A 1-42表达量。
在进一步的长期刺激实验中，即40赫兹闪烁光刺激小鼠，每天刺激一小时，连续刺激7天，结果还显示，与对照组（无光刺激）相比，5XFAD小鼠视觉皮层上的A沉积板块的数量减少了67.2%，A沉积板块的面积减少了63.7%。这表明，LED光刺激眼部可以改善AD小鼠的疾病状态。基于同样的原理，光刺激人眼部也可以达到同样的治疗AD患者的疾病状态。为此，本发明提供了一种利用LED光刺激眼部来治疗、改善以及预防阿尔茨海默病的便携式治疗仪。
参考文献
[1] Siarkosa, K. T. et al. A Review of Pharmacological Treatments for Depression in Alzheimer’s Disease. J. Alzheimer’s Disease 48, 15–34 (2015)
[2] Beydoun, M. A. et al. Nationwide Inpatient Prevalence, Predictors, and Outcomes of Alzheimer's Disease among Older Adults in the United States, 2002-2012. J Alzheimers Dis. 48(2):361-375 (2015)
[3] Gauthier, S. et al. Current and future management of Alzheimer's disease. Alzheimers Dement. 4(1):S48-50 (2008) 
[4a] Oakley, H. et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140 (2006) 
[4b] Bero, A. W. et al. Neuronal activity regulates the regional vulnerability to amyloid-β  deposition. Nature Neurosci. 14, 750–756 (2011)
[4c] Butterfield, D. A. et al. Evidence of oxidative damage in Alzheimer’s disease brain:central role for amyloid β β-peptide. Trends in Mol. Med. 7(12):549-554, 2001.
[5a] Mattsson, N. et al. Plasma tau in Alzheimer disease. Neurology. 87(17):1827-1835 (2016)
[5b] Gratuze, M. et al. Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer's disease. Neurobiol Dis. 98:1-8 (2017) 
[5c] Gratuze, M. et al. High-fat, high-sugar, and high-cholesterol consumption does not impact tau pathogenesis in a mouse model of Alzheimer's disease-like tau pathology.Neurobiol Aging. 47:71-73 (2016) 
[6a] Klimova, B. et al. Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-ReviewAlzheimer's Disease and Chinese Medicine. Curr Alzheimer Res. (2017) Jan 16.
[6b] Liao, X. et al. Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy for Cognitive Impairment in Alzheimer's Disease: A Meta-Analysis. J Alzheimers Dis.  48(2):463-472 (2015)
[6c] Gauthier, S. et al. Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study. J Alzheimers Dis. 48(2):473-481 (2015) 
[6d] Siarkos, K. T. et al. A Review of Pharmacological Treatments for Depression in Alzheimer's Disease. J Alzheimers Dis. 48(1):15-34 (2015)
[6e] Ashford, J. W. et al. A Role for Complementary and Integrative Medicine in Alzheimer's Disease Prevention. J Alzheimers Dis. 48(1):13-14 (2015)
[7a] Gray, C. M., König, P., Engel, A. K. & Singer, W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature 338, 334–337 (1989).
[7b] Eckhorn, R. et al. Coherent oscillations: a mechanism of feature linking in the visual cortex Multiple electrode and correlation analyses in the cat. Biol. Cybern. 60, 121–130 (1988).
[8a] Cardin, J. A. et al. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature 459, 663–667 (2009) 
[8b] Sekiguchi, H. et al. Bright light therapy for sleep disturbance in dementia is most effective for mild to moderateAlzheimer's type dementia: a case series. Psychogeriatrics. (2017)
[9] Hannah F. Iaccarino, Annabelle C. Singer, Anthony J. Martorell1, et al, Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 540, 230-235 (2016)。
 技术问题
提供一种利用LED光源刺激眼部来治疗、改善以及预防阿尔茨海默病的便携式治疗仪。
 技术解决方案
利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：
该治疗仪包括：
可固定于人面部并覆盖眼部的眼罩；
固定在眼罩上的光源；
为光源提供能量的电源；
调节光源变化的控制元件。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述眼罩为不透光的材料制成的眼罩。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：光源固定在眼罩接触面部的一侧。
进一步地：所述光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。
进一步地：所述点光源为发光二级管，所述发光二极管为圆形或方形。
进一步地：所述圆形的发光二级管直径为2 – 5 毫米。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述点光源组成的环状阵列内填充有其他点光源，排布方式为圆心处1个，圆心处与环状之间6个。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：光源的光波长为400 – 800 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为20 – 2000 勒克斯。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述电源是通过电源线连接在光源上的电源装置。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述电源是固定在眼罩上的电池。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述控制元件为固定在电源装置上的调节光亮度频率的控制器。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述控制元件为固定在眼罩上的通过接受移动通讯设备发送的指令来调控光亮度频率的控制器。
所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述环形光源阵列为12个点光源组成。
 有益效果
该便携式治疗仪具有操作简单、应用方便、性价比高的特点。该便携式治疗仪不仅适用于各级医疗机构（高端的三甲医院、社区医院、乡镇医院），而且还适用于各类康复机构、老年健康管理机构以及各个家庭中使用。该便携式治疗仪不仅可以用于固定的场所等，而且还可以作为可穿戴治疗仪随身携带，使用不受地点和时间的限制。本便携式治疗仪将主要用于阿尔茨海默病患者的治疗和改善、以及中老年人群的阿尔茨海默病预防。
 附图说明
图1、图2是眼罩以及LED光源在眼罩内侧的分布示意图；
图3是眼罩上LED光源的光亮度调制示意图。T2是LED光源点亮时间。
图中：
1用于覆盖眼部的眼罩；
2镶嵌在眼罩上的排列成环状图案的LED光源。
 本发明的最佳实施方式
本实施例包括如下技术特征：
治疗仪包括：
可固定于人面部并覆盖眼部的眼罩；
固定在眼罩上的光源；
为光源提供能量的电源；
调节光源变化的控制元件。
其中：所述眼罩为不透光的材料制成的眼罩。其中的光源固定在眼罩接触面部的一侧；光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。光源采用圆形发光二级管，直径为2毫米；点光源组成的环状阵列内填充有其他点光源，排布方式为圆心处1个，圆心处与环状之间6个。光源的光波长为600 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为1500 勒克斯。
 本发明的实施方式
本发明是一种利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其技术思想是通过LED光刺激病患眼部，来达到治疗、改善以及预防阿尔茨海默病的效果。
本发明具体结构及特点包括：
利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：
该治疗仪包括：
可固定于人面部并覆盖眼部的眼罩；
固定在眼罩上的光源；
为光源提供能量的电源；
调节光源光亮度变化的控制元件。
所述眼罩为不透光的材料制成的眼罩，以黑色为佳。
光源固定在眼罩接触面部的一侧。
所述光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。光源较佳的布置为横向椭圆形环状。
所述点光源为发光二级管，所述发光二极管为圆形或方形，对于圆形的，优选直径为2 – 5 毫米。
另一种光源布置形式是，在点光源组成的环状阵列内填充有其他点光源，优选排布方式为圆心处1个，圆心处与环状之间6个。
本发明达到治疗效果的重点在于光源的参数，如图3所示，具体为：光源的光波长为400 – 800 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为20 – 2000 勒克斯。经过发明人大量实验和研究，以上参数的光源可有效治疗和改善患者的疾病状态。
所述电源是通过电源线连接在光源上的电源装置。或者固定在眼罩上的电池。
所述控制元件为固定在电源装置上的调节光亮度频率的控制器。或者为固定在眼罩上的通过接受移动通讯设备发送的指令来调控光亮度频率的控制器。
所述环形光源阵列为12个点光源组成，效果更佳。
所述移动通讯设备包括手机、腕表或可穿戴式设备。
本发明的使用方法如下：
用弹性的固定带将眼罩固定在面部并覆盖眼部，调节弹性的固定带至舒适程度。将眼罩电源连接线连接至电源，启动光闪烁治疗程序。可以根据个人舒适程度，通过设定T2时间调节光亮度，T2时间的设定范围是1 - 20 ms（T1时间已经固定为25 ms）。点击“启动”开始光闪烁刺激。根据个人具体状况，可以选择光闪烁刺激的治疗方案中的一种：（1）为15分钟/次，4次/天；（2）30分钟/次，2次/天；（3）60分钟/次，1次/天。每七天为一个疗程。
实施例1：
本实施例包括如下技术特征：
治疗仪包括：
可固定于人面部并覆盖眼部的眼罩；
固定在眼罩上的光源；
为光源提供能量的电源；
调节光源变化的控制元件。
其中：所述眼罩为不透光的材料制成的眼罩。其中的光源固定在眼罩接触面部的一侧；光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。光源采用圆形发光二级管，直径为2毫米；点光源组成的环状阵列内填充有其他点光源，排布方式为圆心处1个，圆心处与环状之间6个。光源的光波长为600 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为1500 勒克斯。
实施例2：
本实施例包括如下技术特征：
治疗仪包括：
可固定于人面部并覆盖眼部的眼罩；
固定在眼罩上的光源；
为光源提供能量的电源；
调节光源变化的控制元件。
其中：所述眼罩为不透光的材料制成的眼罩。其中的光源固定在眼罩接触面部的一侧；光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。光源采用圆形发光二级管，直径为5毫米；光源的光波长为600 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为20勒克斯。
实施例3：
本实施例包括如下技术特征：
治疗仪包括：
可固定于人面部并覆盖眼部的眼罩；
固定在眼罩上的光源；
为光源提供能量的电源；
调节光源变化的控制元件。
其中：所述眼罩为不透光的材料制成的眼罩。其中的光源固定在眼罩接触面部的一侧；光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。光源采用圆形发光二级管，直径为5毫米；光源的光波长为600 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为2000勒克斯。
以上对本发明专利所提供的进行了初步的描述。以上实施例的说明只是用于帮助理解本发明的核心思想。应该指出，对于本技术领域的技术人员来说，在不脱离本发明专利原理的前提下，可以对本发明专利进行若干改进和修饰，这些改进和修饰也在本发明专利权利要求的保护范围之内。

Claims (13)

  1. 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：
    该治疗仪包括：
    可固定于人面部并覆盖眼部的眼罩；
    固定在眼罩上的光源；
    为光源提供能量的电源；
    调节光源变化的控制元件。
  2. 根据权利要求1所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述眼罩为不透光的材料制成的眼罩。
  3. 根据权利要求1所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：光源固定在眼罩接触面部的一侧。
  4. 根据权利要求3所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述光源为多个点光源组成的环形光源阵列，有两个环形光源阵列排布在眼罩上，当眼罩覆盖双眼时，两个环形光源阵列覆盖在双眼上。
  5. 根据权利要求4所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述点光源为发光二级管，所述发光二极管为圆形或方形。
  6. 根据权利要求5所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述圆形的发光二级管直径为2 – 5 毫米。
  7. 根据权利要求4所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述点光源组成的环状阵列内填充有其他点光源，排布方式为圆心处1个，圆心处与环状之间6个。
  8. 根据权利要求1所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：光源的光波长为400 – 800 纳米，光亮度调制频率为40赫兹，其中光亮时间为1 – 20 毫秒可调，光照度为20 – 2000 勒克斯。
  9. 根据权利要求1所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述电源是通过电源线连接在光源上的电源装置。
  10. 根据权利要求1所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述电源是固定在眼罩上的电池。
  11. 根据权利要求9所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述控制元件为固定在电源装置上的调节光亮度频率的控制器。
  12. 根据权利要求9或10所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述控制元件为固定在眼罩上的通过接受移动通讯设备发送的指令来调控光亮度频率的控制器。
  13. 根据权利要求4所述的利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪，其特征在于：所述环形光源阵列为12个点光源组成。
PCT/CN2018/079879 2017-03-27 2018-03-21 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪 WO2018177182A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201880006540.7A CN111867676A (zh) 2017-03-27 2018-03-21 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710188035.6A CN107019849A (zh) 2017-03-27 2017-03-27 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪
CN201710188035.6 2017-03-27

Publications (1)

Publication Number Publication Date
WO2018177182A1 true WO2018177182A1 (zh) 2018-10-04

Family

ID=59525377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/079879 WO2018177182A1 (zh) 2017-03-27 2018-03-21 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪

Country Status (2)

Country Link
CN (2) CN107019849A (zh)
WO (1) WO2018177182A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107019849A (zh) * 2017-03-27 2017-08-08 关夫 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪
CN108310665B (zh) * 2017-12-20 2020-08-11 贵州民族大学 一种基于led灯珠阵列的光治疗仪
US20220362576A1 (en) * 2019-06-17 2022-11-17 Zhejiang Brainhealth Medical Technology Co., Ltd. Phototherapy device and phototherapy instrument used for irradiation of the head, and therapy method thereof
CN110251798A (zh) * 2019-07-18 2019-09-20 中国计量大学 一种用于阿尔茨海默病的头戴式声光治疗仪
CN115779277B (zh) * 2022-11-03 2024-04-12 东北大学 一种面向脑重大疾病的红外光神经调控方法、存储介质

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN201543118U (zh) * 2009-11-25 2010-08-11 胡明云 保健眼镜
CN101869740A (zh) * 2010-06-23 2010-10-27 上海理工大学 治疗脑中枢神经***疾病的头罩装置
CN102300604A (zh) * 2008-12-30 2011-12-28 皇家飞利浦电子股份有限公司 用于向受试者提供光疗的***和方法
CN203634651U (zh) * 2013-11-27 2014-06-11 杨小浩 Led光疗面膜
KR20140090332A (ko) * 2013-01-07 2014-07-17 대한민국(전북기계공업고등학교장) 테라피 글라스
US20160016004A1 (en) * 2014-07-17 2016-01-21 Troy HUDSON Light therapy glasses and mobile application
CN106039578A (zh) * 2016-05-11 2016-10-26 付金龙 一种穿戴式治疗设备以及设备控制方法
US20170056650A1 (en) * 2015-08-31 2017-03-02 Zoll Medical Corporation Electrode Use Indication
CN107019849A (zh) * 2017-03-27 2017-08-08 关夫 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN201308726Y (zh) * 2008-12-02 2009-09-16 南通同润生物科技有限公司 近红外光激活大脑活性的健脑仪
JP5887139B2 (ja) * 2008-12-30 2016-03-16 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 光療法システム及び方法
CN203710557U (zh) * 2014-03-09 2014-07-16 山东中医药大学 脑血管病人康复用头部按摩器
CN104162233A (zh) * 2014-09-04 2014-11-26 电子科技大学 用于治疗脑疾病的近红外光治疗仪
US20160235980A1 (en) * 2015-02-06 2016-08-18 NooThera Technologies LLC Systems and methods for directed energy therapeutics
JP6714606B2 (ja) * 2015-03-20 2020-06-24 ルー リム 脳の非侵襲的神経刺激療法のための方法、システム及び装置

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102300604A (zh) * 2008-12-30 2011-12-28 皇家飞利浦电子股份有限公司 用于向受试者提供光疗的***和方法
CN201543118U (zh) * 2009-11-25 2010-08-11 胡明云 保健眼镜
CN101869740A (zh) * 2010-06-23 2010-10-27 上海理工大学 治疗脑中枢神经***疾病的头罩装置
KR20140090332A (ko) * 2013-01-07 2014-07-17 대한민국(전북기계공업고등학교장) 테라피 글라스
CN203634651U (zh) * 2013-11-27 2014-06-11 杨小浩 Led光疗面膜
US20160016004A1 (en) * 2014-07-17 2016-01-21 Troy HUDSON Light therapy glasses and mobile application
US20170056650A1 (en) * 2015-08-31 2017-03-02 Zoll Medical Corporation Electrode Use Indication
CN106039578A (zh) * 2016-05-11 2016-10-26 付金龙 一种穿戴式治疗设备以及设备控制方法
CN107019849A (zh) * 2017-03-27 2017-08-08 关夫 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪

Also Published As

Publication number Publication date
CN111867676A (zh) 2020-10-30
CN107019849A (zh) 2017-08-08

Similar Documents

Publication Publication Date Title
WO2018177182A1 (zh) 利用光刺激视觉神经治疗阿尔茨海默病的便携式治疗仪
AU2018333124B2 (en) System and method for automated personalized brain modulation with photobiomodulation
JP6539240B2 (ja) 医学的障害の治療のためのデバイス
Sabel et al. Vision modulation, plasticity and restoration using non-invasive brain stimulation–An IFCN-sponsored review
US8868177B2 (en) Non-invasive treatment of neurodegenerative diseases
US20090005837A1 (en) Method and apparatus for stimulating the neurochemistry of the brain resulting in increased overall brain function, cognitive performance, and intelligence quota
US6669627B1 (en) REM sleep augmentation with extra-ocular light
US6135117A (en) Non-ocular circadian clock resetting in humans
Merabet et al. Suppression of complex visual hallucinatory experiences by occipital transcranial magnetic stimulation: a case report
JP6260953B2 (ja) 認知症状やうつ様症状改善のための光照射装置、この光照射装置を備えた部屋、及び認知症状やうつ様症状改善のための照明器具
JP2017192812A5 (zh)
WO2012024243A1 (en) Minimally invasive low level light therapy for neurological disorders
CN101869740B (zh) 治疗脑中枢神经***疾病的头罩装置
KR101885678B1 (ko) 베타아밀로이드 플라크의 축적 억제용 광선조사 제어장치
Wang et al. Neural mechanism underlying task-specific enhancement of motor learning by concurrent transcranial direct current stimulation
Vandewalle et al. Neuroimaging the effects of light on non-visual brain functions
JP2018166568A (ja) ガンマ波誘発装置およびガンマ波誘発方法
Nam et al. Effects of galvanic vestibular stimulation on vestibular compensation in unilaterally labyrinthectomized mice
CN114464293A (zh) 一种感官刺激认知障碍康复训练***
RU128494U1 (ru) Устройство для воздействия на биоритмы человека
Klaver Effect of stimulation of mRGCs on Alzheimer's and Parkinson's disease
Casey Electricity in the brain
Abdulfattah AlDajani et al. Evaluating the Potential of Light Exposure on Reducing the Frequency of Epileptic Seizures
US20200046976A1 (en) Non-invasive treatment of neurodegenerative diseases
Motevalizadeh et al. Transcranial Direct Current Stimulation (tDCS) as a Therapeutic Tool for Chronic Insomnia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18776210

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18776210

Country of ref document: EP

Kind code of ref document: A1